标题
Clinical development of mTor inhibitors for renal cancer
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 11, Pages 1229-1237
出版商
Informa UK Limited
发表日期
2017-09-27
DOI
10.1080/13543784.2017.1384813
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
- (2017) Hope S Rugo et al. LANCET ONCOLOGY
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
- (2016) Andrew J Armstrong et al. LANCET ONCOLOGY
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
- (2015) I. D. Davis et al. ANNALS OF ONCOLOGY
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
- (2015) A. Ravaud et al. ANNALS OF ONCOLOGY
- Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study
- (2015) Jaime R. Merchan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
- (2015) S. Pal et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma
- (2015) Matthew T. Campbell et al. Clinical Genitourinary Cancer
- Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents
- (2015) Andrea Coinu et al. Expert Review of Anticancer Therapy
- BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)
- (2015) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer
- (2014) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2014) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Making new contacts: the mTOR network in metabolism and signalling crosstalk
- (2014) Mitsugu Shimobayashi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
- (2014) E. R. Plimack et al. ONCOLOGIST
- Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
- (2013) G Procopio et al. BRITISH JOURNAL OF CANCER
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium
- (2013) John D. Hainsworth et al. CANCER INVESTIGATION
- A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2013) Rhonda L. Bitting et al. Clinical Genitourinary Cancer
- Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis
- (2013) Tomohiro Funakoshi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
- (2013) Sergio Bracarda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis
- (2013) Jian Xu et al. CURRENT MEDICAL RESEARCH AND OPINION
- Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
- (2013) M.N. Fishman et al. EUROPEAN JOURNAL OF CANCER
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review
- (2011) C. B. Boers-Doets et al. ONCOLOGIST
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of mTOR
- (2010) H.-J. Klumpen et al. ONCOLOGIST
- Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series
- (2009) Gianluigi Lunardi et al. CLINICAL THERAPEUTICS
- A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma
- (2009) Christopher W. Ryan et al. INVESTIGATIONAL NEW DRUGS
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations
- (2009) Joseph P. Boni et al. SEMINARS IN ONCOLOGY
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
- (2008) C Le Tourneau et al. BRITISH JOURNAL OF CANCER
- Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
- (2008) B. I. Rini CLINICAL CANCER RESEARCH
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
- (2008) Chiaki Tanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now